Verrica Pharmaceuticals Inc.（简称：Verrica制药）宣布，其合作伙伴鸟居药品株式会社已在日本市场正式推出Ycanth®（cantharidin，0.7% topical solution），该产品获批用于治疗传染性软疣。这一重要进展标志着Verrica制药的核心产品成功进入全球主要医药市场之一，将为日本患者提供一种全新的非侵入性治疗选择。Ycanth®是首个且目前唯一经美国FDA批准、采用专有技术平台开发的传染性软疣局部治疗药物，其活性成分斑蝥素通过靶向病变部位实现有效治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.